Overview

A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

Status:
Recruiting
Trial end date:
2023-10-24
Target enrollment:
Participant gender:
Summary
The main goals of this study are to further determine whether the study drug donanemab is safe and effective in participants with Alzheimer's disease and to validate video scale assessments.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company